Search clinical trials for: CFZ533

Total 14 results

Novartis Pharmaceuticals

Completed

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

United States, Hungary, Germany, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Graves' Disease

Germany, United States
Novartis Pharmaceuticals

Completed

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.

Lupus Nephritis

China, Taiwan, Hungary, Korea, Republic of, Germany, Turkey, Argentina, Russian Federation, Hong Kong, Tunisia
Novartis Pharmaceuticals

Completed

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Kidney Transplantation

United States, Netherlands, Germany, Brazil
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)

Sjögren Syndrome

United States, United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Canada, Colombia, Romania, Argentina, Chile, Brazil, S...
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects (CCFZ533X2207)

Type 1 Diabetes Mellitus

Belgium, Italy, Spain, United Kingdom, Germany, Slovenia
Novartis Pharmaceuticals

Completed

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Myasthenia Gravis, Generalized

Taiwan, Germany, Russian Federation, Denmark, Canada
Novartis Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

United States, Taiwan
Novartis Pharmaceuticals

Active, not recruiting

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Systemic Lupus Erythematosus (SLE)

Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension (CONTRAIL I)

Liver Transplant Rejection

United States, Belgium, Germany, Spain, Argentina, Netherlands, Italy, Hungary, France, Czechia
Sultan Qaboos University

Not yet recruiting

Efficacy of Hydroxyzine for Patients With Panic Disorder

Panic Disorder
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome (TWINSS Extn)

Sjogren's Syndrome

United Kingdom, Netherlands, Australia, Austria, Israel, France, Germany, Greece, Hungary, Italy, United States, Korea, Republic of, Japan, Portugal, Russian Federation, Turkey, Colombia, Romania, Argentina, Chile, Brazil, Canada, S...
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (CIRRUS I)

Kidney Transplant Rejection

United States, Hungary, Japan, United Kingdom, Belgium, Spain, Netherlands, Germany, Australia, France, Korea, Republic of, Switzerland, Norway, Italy, Latvia, Sweden, Argentina, Brazil, Canada, Czechia

Search clinical trials for: CFZ533

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations